In Vitro and In Vivo Diagnostic Substances - Latest Activist Disclosures

This table shows recent activist investor (Schedule 13D) filings made in this industry. Any investor or hedge fund that makes an investment with the intention of influencing management is considered an activist investor and must file a 13D.

Date Form Target Company Investor Shares Ownership
(Percent)		 Ownership Change
(Percent)
2016-10-26 13D/A ICCC / ImmuCell Corporation Pessin Norman H 480,000 1.00 92.00
2016-05-20 13D NTLA / Intellia Therapeutics, Inc. Orbimed Advisors Llc 2,662,180 7.40
2016-05-11 13D NTLA / Intellia Therapeutics, Inc. Novartis Institutes for BioMedical Research, Inc. 5,573,658 15.48
2016-02-25 13D/A ICCC / ImmuCell Corporation Rothschild Jonathan E 510,158 12.20
2016-02-03 13D ICCC / ImmuCell Corporation Pessin Norman H 250,000 1.00
2015-08-03 13D/A BGMD / BG Medicine, Inc. Agtc Advisors Fund Lp 2,826,416 27.60 -47.94
2015-05-26 13D/A BGMD / BG Medicine, Inc. Agtc Advisors Fund Lp 5,428,982 15.50
2014-12-19 13D/A BGMD / BG Medicine, Inc. Newcogen Group Llc 5,424,777 15.50
2014-06-27 13D/A ICCC / ImmuCell Corporation Rothschild Jonathan E 510,436 16.90
2014-04-04 13D/A RGDXQ / Response Genetics, Inc Northern Right Capital Management, L.P. 1,530,926 4.00
2014-02-14 13D/A RGDXQ / Response Genetics, Inc Northern Right Capital Management, L.P. 2,204,569 6.40
2013-07-26 13D/A RGDXQ / Response Genetics, Inc Northern Right Capital Management, L.P. 2,602,029 7.90
2013-02-26 13D/A BGMD / BG Medicine, Inc. Newcogen Group Llc 8,704,862 31.00
2012-11-26 13D/A QDEL / QuidelOrtho Corporation Schuler Jack W 4,345,719 13.00
2012-05-29 13D/A QDEL / QuidelOrtho Corporation Schuler Jack W 3,845,719 11.60
2012-02-06 13D/A RGDXQ / Response Genetics, Inc Northern Right Capital Management, L.P. 3,226,064 15.20